Home > Insider Trading > Filing (0001242616-12-000014)

Filing Details

Accession Number:: 0001242616-12-000014
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-05-31 16:07:36
Reporting Period:: 2012-05-29

Filing Date:: 2012-05-31
Accepted Time:: 2012-05-31 16:07:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
792977	Amag Pharmaceuticals Inc.	AMAG	Pharmaceutical Preparations (2834)	042742593

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1408474	Phd Md F Lee Allen	C/O Amag Pharmaceuticals, Inc. 100 Hayden Avenue Lexington MA 02421	Evp, Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-05-29	1,354	$0.00	3,583	No	4	C	Direct
Common Stock	Disposition	2012-05-29	1,354	$0.00	2,229	No	4	S	Direct
Common Stock	Acquisiton	2012-05-30	12,500	$0.00	14,729	No	4	C	Direct
Common Stock	Disposition	2012-05-30	12,500	$0.00	2,229	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	S	Direct
No	4	C	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Acquisiton	2012-05-29	1,354	$0.00	1,354	$0.00
Common Stock	Restricted Stock Unit	Acquisiton	2012-05-30	12,500	$0.00	12,500	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,354			No	4	C	Direct
12,500			No	4	C	Direct

Footnotes

The shares were acquired by the reporting person as a result of the partial vesting of a restricted stock unit grant described below.
Not applicable.
The restricted stock units were scheduled to lapse on February 24, 2012. However, due to Company's black out policies and certain tax laws, the shares were not delivered to the reporting person until May 29, 2012.
The shares sold on this date were sold in multiple transactions. The actual sales prices range from $14.111-$14.1201. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
The restricted stock units were scheduled to lapse on January 7, 2012. However, due to Company's black out policies and certain tax laws, the shares were not delivered to the reporting person unitl May 30, 2012.
The shares sold on this date were sold in multiple transactions. The actual sales prices range from $13.57-$13.79. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
Each restricted stock unit represents a contingent right to receive one share of common stock.
Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal, annual installments commencing February 24, 2011. The second installment of 1,354 restricted stock units was scheduled to vest on February 24, 2012 but delivery of the shares was deferred as described herein.
Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in three installments. The first installment of 12,500 restricted stock units was scheduled to vest on January 7, 2012 but delivery of the shares was deferred as described herein. The remaining two installments of 6,250 restricted stock units each will vest on January 7, 2013 and January 7, 2014, respectively.